Japan first to approve Novartis' blockbuster hopeful Cosentyx; Bayer, Hospira win FDA nods;

> Japan has approved Novartis' ($NVS) Cosentyx as a treatment for psoriasis and psoriatic arthritis. Release

> The FDA has green-lighted Bayer's Gadavist injection as the first magnetic resonance contrast agent for pediatric patients less than 2 years of age. Release

> The FDA has given Hospira ($HSP) a thumbs-up for its analgesic Dyloject injection, a treatment for pain management. Release

> Angelini will market Ariad's ($ARIA) Iclusig in Eastern Europe. Report

> Pfizer ($PFE) has granted Georgia State $850,000 to partner with Chinese health officials to expand tobacco control efforts in China's major cities. More

> The Asia-Pacific market for Type 2 diabetes treatments will hit $10.5 billion by 2020, GBI Research predicts. Release

And Finally... The Gates Foundation is using art to encourage vaccination. Story (sub. req.)